Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1954 1
1955 1
1956 2
1957 3
1958 3
1959 5
1960 5
1961 5
1962 6
1963 9
1964 12
1965 5
1966 7
1967 7
1968 8
1969 9
1970 13
1971 10
1972 8
1973 2
1974 11
1975 12
1976 11
1977 19
1978 22
1979 22
1980 31
1981 32
1982 30
1983 25
1984 43
1985 57
1986 62
1987 66
1988 63
1989 62
1990 60
1991 65
1992 75
1993 103
1994 78
1995 88
1996 114
1997 116
1998 101
1999 94
2000 109
2001 117
2002 135
2003 117
2004 142
2005 163
2006 201
2007 197
2008 202
2009 177
2010 217
2011 225
2012 235
2013 230
2014 289
2015 277
2016 299
2017 340
2018 333
2019 349
2020 385
2021 236
Text availability
Article attribute
Article type
Publication date

Search Results

5,969 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. Among authors: yamashita t. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, Eshima K, Tanizawa K, Fukuzawa M, Hayashi T, Akishita M, Lip GYH, Yamashita T; ELDERCARE-AF Committees and Investigators. Okumura K, et al. Among authors: yamashita t. N Engl J Med. 2020 Oct 29;383(18):1735-1745. doi: 10.1056/NEJMoa2012883. Epub 2020 Aug 30. N Engl J Med. 2020. PMID: 32865374 Clinical Trial.
Osteoclast differentiation by RANKL and OPG signaling pathways.
Udagawa N, Koide M, Nakamura M, Nakamichi Y, Yamashita T, Uehara S, Kobayashi Y, Furuya Y, Yasuda H, Fukuda C, Tsuda E. Udagawa N, et al. Among authors: yamashita t. J Bone Miner Metab. 2021 Jan;39(1):19-26. doi: 10.1007/s00774-020-01162-6. Epub 2020 Oct 20. J Bone Miner Metab. 2021. PMID: 33079279 Review.
MK-7 and Its Effects on Bone Quality and Strength.
Sato T, Inaba N, Yamashita T. Sato T, et al. Among authors: yamashita t. Nutrients. 2020 Mar 31;12(4):965. doi: 10.3390/nu12040965. Nutrients. 2020. PMID: 32244313 Free PMC article. Review.
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. André F, et al. Among authors: yamashita t. Ann Oncol. 2021 Feb;32(2):208-217. doi: 10.1016/j.annonc.2020.11.011. Epub 2020 Nov 25. Ann Oncol. 2021. PMID: 33246021 Free article. Clinical Trial.
CDK1 dependent phosphorylation of hTERT contributes to cancer progression.
Yasukawa M, Ando Y, Yamashita T, Matsuda Y, Shoji S, Morioka MS, Kawaji H, Shiozawa K, Machitani M, Abe T, Yamada S, Kaneko MK, Kato Y, Furuta Y, Kondo T, Shirouzu M, Hayashizaki Y, Kaneko S, Masutomi K. Yasukawa M, et al. Among authors: yamashita t. Nat Commun. 2020 Mar 25;11(1):1557. doi: 10.1038/s41467-020-15289-7. Nat Commun. 2020. PMID: 32214089 Free PMC article.
Recent insights into peroxisome biogenesis and associated diseases.
Fujiki Y, Abe Y, Imoto Y, Tanaka AJ, Okumoto K, Honsho M, Tamura S, Miyata N, Yamashita T, Chung WK, Kuroiwa T. Fujiki Y, et al. Among authors: yamashita t. J Cell Sci. 2020 May 11;133(9):jcs236943. doi: 10.1242/jcs.236943. J Cell Sci. 2020. PMID: 32393673 Review.
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H, Satou Y, Yamashita T, Hoffman EP; CINRG DNHS Investigators. Clemens PR, et al. Among authors: yamashita t. JAMA Neurol. 2020 Aug 1;77(8):982-991. doi: 10.1001/jamaneurol.2020.1264. JAMA Neurol. 2020. PMID: 32453377 Free PMC article. Clinical Trial.
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S. Rugo HS, et al. Among authors: yamashita t. Ann Oncol. 2020 Aug;31(8):1001-1010. doi: 10.1016/j.annonc.2020.05.001. Epub 2020 May 13. Ann Oncol. 2020. PMID: 32416251 Free article. Clinical Trial.
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Morizane C, et al. Among authors: yamashita t. Ann Oncol. 2019 Dec 1;30(12):1950-1958. doi: 10.1093/annonc/mdz402. Ann Oncol. 2019. PMID: 31566666 Free article. Clinical Trial.
5,969 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page